Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:12:03.783Z.
Calculation as of: 2026-10-06T14:12:03.783Z.
Quote observation: 2026-10-06T14:02:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 28ff4bc206842fc4bf4b39bc6a519bf9e708a216f8b2554427075e3ddc5a9144
PE RATIO
N/A
Market Cap
$11.38M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $10.83M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.91M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.38M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.55M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.55M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.04M | N/A | 9.63 | 9.63 | 9.63 |
| BioVie Inc. (BIVI)vs › | $11.01M | N/A | N/A | N/A | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.32M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.42M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.35M | N/A | 2.43 | 2.43 | 2.43 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
